
Opinion|Videos|November 12, 2025
Applying Third-Line Therapy in mCRC: Community vs Academic Settings
Panelists discuss how community and academic settings differ in applying third-line therapies for metastatic colorectal cancer and how collaboration benefits patients.
Advertisement
Episodes in this series

Panelists describe clinical scenarios where patients may receive third-line therapy in community vs academic settings, noting differences in resources, expertise, and support.
Community practices may offer more accessibility and continuity of care, whereas academic centers may be better suited for complex cases or clinical trial enrollment.
They emphasize the importance of collaboration between settings to ensure equitable and consistent care for patients, regardless of treatment location.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success
2
OneOncology Partners With OpenEvidence to Give Physicians Access Within Clinical Workflows
3
High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial
4
Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups
5





